Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — MST Access Australian Micro & Small Caps Conference 2021
29 slides from Rhythm Biosciences's conference presentation, Jun 17, 2021
Slide 1: Rhythm to Present at MST Access Investor Conference
ASX Announcement ASX: RHY Rhythm to Present at MST Access Investor Conference 17 June 2021, Melbourne: Rhythm Biosciences (ASX: RHY) is pleased to announce that it has been invited to present at the MST Access Australian Micro & Small Caps Conference 2021. Presentation is to be given by CEO Mr Glenn
Slide 2: MST Access Australian Micro & Small Caps Conference 2021
MST ACCESS Australian Micro & Small Caps Conference 2021 Initial Product Aim = ColoSTAT® the early detection of colorectal cancer using a simple, accurate & low-cost blood test, designed for global mass-market screening. A transformative, predictive cancer diagnostics technology company ASX: RHY © R
Slide 3: Important Notice
Important Notice • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations o
Slide 4: Corporate Overview
Corporate Overview Rhythm Biosciences (ASX: RHY) Financial Information ASX Code: RHY A transformative, predictive cancer Share Price (14-Jun-21) $0.98 diagnostics technology company 12-Month Range $0.078 - $1.67 ✓ RHY is a new-generation / disruptive Shares on Issue ~202.170m cancer diagnostics tech
Slide 5: Board and Management
Board and Management A strong and industry experienced board and management team, with a pedigree of building successful businesses. OTTO BUTTULA GLENN GILBERT TREVOR LOCKETT LOU PANACCIO DAVID WHITE EDUARDO VOM Chief Executive Technical – Non-Executive Non-Executive Non-Executive Chairman Officer E
Slide 6: Key Investment Highlights
Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Transformative Diagnostic Company: Focused on early detection of colorectal cancer (CRC) using a simple, low-cost blood test that could rev
Slide 7: Key Investment Highlights
Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Sound technology: 13 years of R&D pioneered by CSIRO^ combined with 3 years RHY, giving robustness and confidence in the biomarkers selecte
Slide 8: Colorectal Cancer – Mass-Market Screening Is Critical
Colorectal Cancer – Mass-Market Screening Is Critical Colorectal cancer is the second largest cause of cancer-related deaths in the industrialised world with over 850,000 deaths annually. Curable in over 90% of cases if detected early. This drops to circa 10% if detected late and once the cancer has
Slide 9: Bowel Cancer Treatment Costs Are Increasing
Bowel Cancer Treatment Costs Are Increasing Early detection is the key to survival and reducing the cost of treatment $130,000 $120,000 ? $110,000 Cost drivers: $100,000 • Private hospital Average treatment cost per person $100,000 • Public hospital $90,000 51% • Outpatient $80,000 increase • Doctor
Slide 10: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? A simple, accurate, low cost blood test for the early detection of colorectal cancer designed for the global mass market ✓ Detects protein biomarkers in the blood that are indicative of an increased likelihood of presence of colorectal cancer. (accurate) ✓ B
Slide 11: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? A simple, accurate, low cost blood test for the early detection of colorectal cancer designed for the global mass market Serum ColoSTAT® ColoSTAT® preparation Immunoassays Algorithm Routine blood Diagnostic Standard lab processes collection report Technology
Slide 12: Current FIT Pathway - Cumbersome And Not Well Adopted
Current FIT Pathway - Cumbersome And Not Well Adopted FIT Testing Central FIT Sample Pathology Collection lab Process Diagnostic assessment to GP * ➢ Multi step faecal collection, packaging over at least 2 days then posting sample back to a central laboratory. Obligation on patient to sample and lab
Slide 13: ColoSTAT - Patient Friendly - Increased Compliance
ColoSTAT® - Patient Friendly - Increased Compliance “83% of unscreened participants preferred a blood test over a faecal test” * Simple & Routine Patient Journey With ColoSTAT® GP referral Any Routine blood draw Pathology lab Diagnostic assessment to GP ColoSTAT® - has the potential to: ✓Significant
Slide 14: ColoSTAT's Competitive Advantage
ColoSTAT®’s - Competitive Advantage Rhythm Faecal Immunochemical Test (FIT) Patient Preference Patient Preference Accuracy Accuracy Early Stage Detection Early Stage Detection Affordability Affordability Simple Process Simple Process Opportunistic Screening* Opportunistic Screening* ColoSTAT®’s comb
Slide 15: ColoSTAT - Development History
ColoSTAT® - Development History • ColoSTAT® relies on detecting biomarkers in blood that indicate an increased likelihood of presence of colorectal cancer. • For over 13 years CSIRO investigated over 68 potential biomarkers until a panel of 10 lead targets remained, using individually sourced commer
Slide 16: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting Trial Study Design End Points Key Recruitment Challenge: Prospective, Cross sectional, Primary: multicentre clinical trial. Performance of ColoSTAT® for ➢ Hospitals maintaining motivated key detection of CRC relative to trial staff members
Slide 17: Study – New Trial Sites Motivated To Recruit
Study 7 – New Trial Sites Motivated To Recruit “The burden of colorectal cancer and the benefits of early detection have been well recognised. The risk of colorectal cancer increases dramatically over 50 years of age, yet the majority of people in this age group remain unscreened. A blood-based diag
Slide 18: Confidence In Performance Moving Forward
Confidence In Performance Moving Forward ✓ Preliminary results from the prototype test-kit outperformed the current market standard (faecal test) and previous CSIRO test work. ✓ Confirmation of Study 6 results demonstrating exceptional accuracy / performance – bettering the prior outperformance. ✓ D
Slide 19: Key Achievements - Delivered In 2020/2021
Key Achievements - Delivered In 2020/2021 ✓ Technically validated the key lead and four adjunct biomarkers. ✓ Appointed additional clinical trial (Study 7) sites. ✓ ISO13485 Quality Management System certification maintained. ✓ Completed reagent development program. ✓ Commenced high-volume manufactu
Slide 20: Key Achievements - ColoSTAT Performance
Key Achievements - ColoSTAT® Performance Prototype test-kit results outperform current global market standard Sensitivity is the ability of the test to correctly identify those patients with colorectal cancer, that is, the percentage of people with colorectal cancer who are correctly identified as h
Slide 21: Market Opportunity – Global Screening Numbers
Market Opportunity – Global Screening Numbers Screening compliance & opportunity by market Europe (incl UK) China 19 % 38 % 63 50-74 population Japan 38 USA % 396.6M % 50-74 population 231.2M 321.2M 50-74 population unscreened 50-74 population 93.6M 41.5M 143.4M unscreened 34.7M 25.7M unscreened uns
Slide 22: Market Likely To Expand Significantly
Market Likely To Expand Significantly Colorectal Cancer is prevalent in younger segments of the population ✓ Colorectal cancer is the leading cause of cancer related deaths for 30-to-35- year-olds in both males and females in Australia. ✓ It is also the leading cause of cancer related deaths for 45-
Slide 23: Where Could ColoSTAT Value Be Derived From
Where Could ColoSTAT ® Value Be Derived From Who are the potential Simplified Value Story payers? Government – ColoSTAT® National Screening Program Because the vast majority of patients prefer a blood Government – Increased CRC screening rates test vs tests involving faecal handling National/Regiona
Slide 24: Potential ColoSTAT Total Market Size
Potential ColoSTAT ® Total Market Size (50-74yr old only) $4.68bn $11.56bn $336.5m $19.83bn $2.08bn (Patient/market share 50-74-year olds) Market Penetration 75% $3.51bn $8.67bn $252.4m $14.87bn $1.56bn $28.86bn 50% $2.34bn $5.78bn $168.2m $9.91bn $1.04bn $19.24bn 25% $1.17bn $2.89bn $84.13m $4.96bn
Slide 25: Go To Market Options
Go To Market Options Multiple avenues and market segments reduce risk and support a flexible and scalable business model National Screening Program/MBS Reimbursed Secondary Triage National • With its effectiveness and Screening Triage • As a transition, ColoSTAT® could be used as a follow affordabil
Slide 26: Competitive Landscape – ColoSTAT's Unique Advantage
Competitive Landscape – ColoSTAT®’s Unique Advantage Blood based Epigenomics Novigenix Volition Rx Epi proColon® Rhythm Colox® Nu.q™ ColoSTAT® ~$300 per ~$150 per <$100 ~$250 per test test per test test Clinical Genomics Colvera™ ~$400 per test ColoSTAT®’s comparative low cost & simplicity lends its
Slide 27: IP – Patents Filed In All Major Target Markets
IP – Patents Filed In All Major Target Markets Granted Pending ➢ Licensed from CSIRO United States France Brazil ➢ Worldwide exclusive licence Australia Germany India ➢ Patent wholly owned by Rhythm China (x2) Italy Biosciences Ltd* ➢ Expires 2031 Japan Luxembourg United Kingdom Netherlands ➢ Method
Slide 28: Future Value Inflection Points – 2021
Future Value Inflection Points – 2021 With R&D significantly de-risked, anticipated near-term value inflection points on the path to towards commercialisation include: ➢ Finalisation and execution of European and Australian regulatory submission pathways. ➢ Commence USA / European / China / Asia mar
Slide 29: Thank you
Glenn Gilbert CEO, Rhythm Biosciences Thank you glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL 28
Rhythm Biosciences — MST Access Australian Micro & Small Caps Conference 2021 on 6ix